Novavax, Inc. (NASDAQ:NVAX) went down by -2.03% from its latest closing price when compared to the 1-year high value of $111.77 and move down -16.06%, while NVAX stocks collected +20.83% of gains with the last five trading sessions. The Wall Street Journal reported 16 hours ago that Vaccine Stock Soars, Rewarding Investor’s Big Bet
Novavax, Inc. (NASDAQ:NVAX) Worth an Investment?
Novavax, Inc. (NASDAQ: NVAX) The 36 Months beta value for NVAX stocks is at 1.49, while 3 of the analysts out of 5 who provided ratings for Novavax, Inc. stocks as a “buy” while 0 as overweight, 2 rated it as hold and 0 as sell. The average price we get from analysts is $101.20 which is -$10.05 below current price. NVAX currently has a short float of 14.91% and public float of 54.38M with average trading volume of 9.70M shares.
NVAX Market Performance
NVAX stocks went up by 20.83% for the week, with the monthly jump of 109.67% and a quarterly performance of 460.54%, while its annual performance rate touched 1777.19%. The simple moving average for the period of the last 20 days is 37.35% for NVAX stocks with the simple moving average of 421.82% for the last 200 days.
Analysts’ Opinion on Novavax, Inc. (NASDAQ:NVAX)
Many brokerage firms have already submitted their reports for NVAX stocks, with Ladenburg Thalmann repeating the rating for NVAX shares by setting it to “Neutral”. The predicted price for NVAX socks in the upcoming period according to Ladenburg Thalmann is $105 based on the research report published on July 8, 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVAX stock at the price of $101, previously predicting the value of $50. The rating they have provided for NVAX stocks is “Buy” according to the report published on June 29, 2020.
B. Riley FBR gave “Buy” rating to NVAX stocks, setting the target price at $106 in the report published on June 29, 2020.
NVAX Stocks 90.60% Far from 50 Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, Novavax, Inc. was unable to take a rebound, for now settling with -13.84% of loss for the given period.
The stock volatility was left at 10.58%, however, within the period of a single month, the volatility rate increased by 10.74%, while the shares surge at the distance of +114.19% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +368.73% upper at the present time.
In the course of the last 5 trading sessions, NVAX went up by +20.83%, which changed the moving average for the period of 200 days to the total of +1,418.93% of gains for the stock in comparison to the 20-day moving average settled at $72.68. In addition, Novavax, Inc. saw 2319.60% in overturn over the period of a single year with a tendency to cut further gains.
NVAX Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Novavax, Inc. (NVAX), starting from Glenn Gregory M, who sold 16,749 shares at the price of $59.53 back on Jun 18. After this action, Rushing now owns 1,839 shares of Novavax, Inc., valued at $997,103 with the latest closing price.
YOUNG JAMES F, the Director of Novavax, Inc., bought 1,500 shares at the value of $48.83 during a trade that took place back on Jun 03, which means that YOUNG JAMES F is holding 1,500 shares at the value of $73,245 based on the most recent closing price.
NVAX Stock Fundamentals
The current profitability levels are settled at -694.44 for the present operating margin. The net margin for Novavax, Inc. stands at -711.04. Total capital return value is set at -87.24, while invested capital returns managed to touch -89.70. Equity return holds the value 78.80%, with -53.90% for asset returns.
The value for Enterprise to Sales is 153.89 with debt to enterprise value settled at 0.96. The receivables turnover for Novavax, Inc. is 4.98 with the total asset turnover at the value of 0.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.77.